Introduction. Although the incidence of malignancy has increased after solid organ transplantation, data on lung cancer in this group of patients is scarce. The aim of this study was to determine clinical characteristics and outcome of patients who developed lung cancer after renal transplantation. Methods. Among a cohort of 1658 patients who received a transplant at our institution and were followedup between 1973 and 2014, five patients developed lung cancer. We analyzed risk factors, transplantation characteristics, treatment options and survival. Results. Lung cancer was diagnosed in 5 patients (0.3%). Time to diagnosis after the transplant procedure ranged from 26 to 156 months (mean 115 months). All of them had a smoking history. Tumors were classified as IIB (20%), IIIA (40%), and IV (40%). Histological types included adenocarcinoma (80%) and there was one case of sarcomatoid carcinoma (20%). One patient had concomitant thyroid papillary carcinoma. Radiotherapy was applied in 2 patients, 2 underwent chemotherapy (erlotinib and combination of carboplatinum and etopozide in one patient each), and 2 died within one month after the diagnosis from disseminated malignant disease. Patients with stage IIIA survived 14 and 24 months after the diagnosis. The patient with sarcomatoid cancer underwent thoracotomy with a complete resection, lost his graft function and died 7 months after the diagnosis. Conclusion. Lung cancer is relatively rare malignancy in renal transplant recipients, but associated with high mortality. Smoking is a significant risk factor, thus smoking cessation should be promoted among renal transplant recipients, as well as regular screening for lung cancer.
1. McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrol Dial Transplant 2002; 17: 2212-2219.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant. NEJM 1999; 341: 1725-1730.
3. Purnell TS, Auguste P, Crews DC, et al. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. Am J Kidney Dis 2013; 62: 953-973.
4. Rosselli D, Rueda JD, Diaz CE. Cost-effectiveness of kidney transplantation compared with chronic dialysis in end-stage renal disease. Saudi J Kidney Dis Transpl 2015; 26: 733-738.
5. Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int 2004; 54: 649-658.
6. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009; 24: 3225-3231.
7. Keles Y, Tekin S, Duzenli M, et al. Post-transplantation Malignancy After Kidney Transplantation in Turkey. Transplant Proc 2015; 47: 1418-1420.
8. Zhang J, Ma L, Xie Z, et al. Epidemiology in post-transplant malignancy in Chinese renal transplant recipients: a singlecenter experience and literature review. Med Oncol 2014; 31: 32.
9. Collett D, Mumford L, Banner NR, et al. Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit. Am J Transplant 2010; 10: 1889-1896.
10. ANZDATA Registry. 37th Report, Chapter 10: Cancer. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2015. Available at: http://www.anzdata.org.au
11. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipients. Cold Spring Harb Perspect Med 2013; 3: a015677.
12. Hrvatski zavod za javno zdravstvo, Registar za rak Republike Hrvatske. Incidencija raka u Hrvatskoj 2013. Bilten 38, Zagreb, 2015.